Mackenzie joins the developer of therapeutics for colds, flu and allergy with a long record of executive board level management within the biotechnology and pharmaceutical industries at companies including Cambridge Genetics, Oxford Biomedica, Avidex (now Immunocore). He was most recently SVP for business development and corporate strategy at Medigene and ceo of Roji (London). In addition, MacKenzie was formerly a departmental head in vaccine r&d at Wellcome and a Wellcome lecturer in immunology at the University of London.
CMPT has received €1.5m convertible loan from Inventages Venture Capital to support continuing operations and the upcoming clinical trial of its lead product for the common cold. CMPT has been supported funding from London-based Inventages Venture Capital and New Zealand-based BioPacificVentures since 2005.
CMP Therapeutics appoints ceo
Receives loan to support clinical trial of lead product for common cold
You may also like
Research & Development
Jabil and Kymanox collaboration to deliver end-to-end development, regulatory and manufacturing solutions
Jabil and Kymanox are partnering to combine their regulatory, technical, and manufacturing expertise to help life science companies streamline development and bring complex therapies to market faster